Company intelligence / Profile preview

Uneedle

Enschede, Overijssel, Netherlandsuneedle.com ↗

Ownership: Private
Development stage: Commercial

Overview

Uneedle has developed proprietary silicon microneedles—Bella-mu and Bella-Vue—for precise intradermal and ophthalmic drug/vaccine administration. Their devices are CE marked and FDA cleared. The company partners with pharma/biotech firms to co-develop products using their technology. No active clinical trials of their own therapies are listed on ClinicalTrials.gov as of now. Their Bella-mu device is licensed to companies like Aston sci. for oncology programs.

Therapeutic areas: OncologyOphthalmology
Modalities: Device
Industry: Consumable Medical Devices

Drug pipeline

2 assets

Bella-mu

Commercial

Indications: Cancer vaccines, Intradermal drug delivery

1 more asset in the full pipeline.

Request access →

Partnerships

Aston sci.

Beyond the preview

Go deeper on Uneedle.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uneedle.

Explore the full profile